Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.44 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | CPN1 | P15169 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21003949 | 1.00 | SLC6A1 (0.44) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27675051 | 0.98 | SLC6A1 (0.42) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27584414 | 0.98 | SLC6A1 (0.42) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL27692569 | 0.88 | SLC6A1 (0.40) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL435813 | 0.88 | — | — | |
| SCHEMBL436562 | 0.88 | — | — | |
| SCHEMBL6181576 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL27702575 | 0.86 | CHRM2 (0.37) | SLC6A1SLC6A11SLC6A13CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL27799701 | 0.86 | CHRM2 (0.37) | SLC6A1SLC6A11SLC6A13CHRM2CHRM4 | |
| SCHEMBL28015183 | 0.84 | TPSAB1 (0.36) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101087769-A | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORP (US) | 2007-12-12 | — | — | CN | claimed |
| US-3998827-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1976-12-21 | — | — | US | claimed |
| WO-2025024707-A1 | INHIBITORS OF CDK2/4/6 KINASE | KINNATE BIOPHARMA INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20240425499-A1 | TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2024012519-A1 | PAN-KRAS INHIBITOR | 北京华森英诺生物科技有限公司 | 2024-01-18 | — | — | WO | disclosed |
| CN-116969977-A | PAN-KRAS inhibitors | 北京华森英诺生物科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116710431-A | Small molecule compounds and compositions | 泰洛治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023064218-A1 | TYRO3 INHIBITORS | Halia Therapeutics, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-103443107-B | Thiazolopyrimidine compound | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-20 | — | — | CN | disclosed |
| CN-102757420-B | Heterotactic aryl carboxylic acid compound, preparation method thereof, medicine composition comprising compound and application of compound | SHANGHAI INST MATERIA MEDICA | 2015-02-04 | — | — | CN | disclosed |
| WO-2014142086-A1 | PYRROLIDIN-3-YL ACETATE DERIVATIVE AND PIPERIDIN-3-YL ACETATE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2014-09-18 | — | — | WO | disclosed |
| CN-101087769-A | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORP (US) | 2007-12-12 | — | — | CN | disclosed |
| WO-2006110884-A2 | 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| CN-1681801-A | Quinolylpropylpiperidine derivatives and their use as antimicrobial agents | AVENTIS PHARMA SA (FR) | 2005-10-12 | — | — | CN | disclosed |
| CN-1374959-A | Piperidine quinolyl propyl derivatives, preparation method and compositions containing same | AVENTIS PHARMA SA (FR) | 2002-10-16 | — | — | CN | disclosed |
| EP-1227083-A1 | 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-07-31 | — | — | EP | disclosed |
| EP-0983269-A4 | PROCESS FOR PREPARING HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-0983269-A1 | PROCESS FOR PREPARING HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998054179-A1 | PROCESS FOR PREPARING HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-12-03 | — | — | WO | disclosed |
| US-3998827-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425499-A1 | TYRO3 INHIBITORS | TYRO3, TYR, TH | SLC6A1 362/4885SLC6A11 431/4885TSHR 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.